Aura Biosciences company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

aurabiosciences.com

Founded Year

2009

Stage

IPO | IPO

Total Raised

$229.11M

Date of IPO

10/29/2021

Market Cap

0.49B

Stock Price

16.50

About Aura Biosciences

Aura Biosciences (NASDAQ: AURA) is a biotechnology company that develops therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates.

Aura Biosciences Headquarter Location

85 Bolton St.

Cambridge, Massachusetts, 02140,

United States

617-781-1241

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Aura Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Aura Biosciences is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Aura Biosciences Patents

Aura Biosciences has filed 14 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • Diseases of the eye and adnexa
  • Molecular biology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/31/2020

9/7/2021

Vaccines, Diseases of the eye and adnexa, Transcription factors, Vaccination, Proteins

Grant

Application Date

1/31/2020

Grant Date

9/7/2021

Title

Related Topics

Vaccines, Diseases of the eye and adnexa, Transcription factors, Vaccination, Proteins

Status

Grant

Latest Aura Biosciences News

Aura Biosciences to Participate in Upcoming Investor Conferences

May 25, 2022

05/25/2022 | 07:01am EDT Message : *Required fields Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that members of its executive team will participate in the following upcoming investor conferences: Cowen’s Virtual 3rd Annual Oncology Innovation Summit on Thursday, June 2, 2022. Fireside chat at 9:00 a.m. ET. Presentation at 1:30 p.m. ET. A live webcast of the Cowen fireside chat and Jefferies presentation will be available on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website at https://ir.aurabiosciences.com/events-and-presentations , where a replay of the webcast will be archived for 90 days following the presentation date. About Aura Biosciences Aura Biosciences, Inc. is a clinical-stage biotechnology company developing virus-like drug conjugates (VDCs), a novel class of therapies, for the treatment of multiple oncology indications. Aura’s lead VDC candidate, AU-011 (belzupacap sarotalocan), consists of a virus-like particle conjugated with an anti-cancer agent. AU-011 selectively targets and destroys cancer cells and activates the immune system with the potential to create long-lasting anti-tumor immunity. AU-011 is currently in development for ocular cancers, with an ongoing Phase 2 dose escalation clinical trial evaluating first-line treatment of choroidal melanoma, a vision- and life-threatening form of eye cancer where standard of care with radiotherapy leaves patients with severe comorbidities, including major vision loss. Aura plans to develop AU-011 across its ocular oncology franchise including for the treatment of patients with choroidal metastases. In addition, leveraging Aura’s technology platform, Aura is developing AU-011 more broadly across multiple cancers, starting with a planned Phase 1 clinical trial in patients with non-muscle invasive bladder cancer. Aura is headquartered in Cambridge, MA. For more information, visit aurabiosciences.com, or follow us on Twitter and LinkedIn. View source version on businesswire.com: https://www.businesswire.com/news/home/20220525005111/en/ © Business Wire 2022

Aura Biosciences Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Aura Biosciences Rank

  • When was Aura Biosciences founded?

    Aura Biosciences was founded in 2009.

  • Where is Aura Biosciences's headquarters?

    Aura Biosciences's headquarters is located at 85 Bolton St., Cambridge.

  • What is Aura Biosciences's latest funding round?

    Aura Biosciences's latest funding round is IPO.

  • How much did Aura Biosciences raise?

    Aura Biosciences raised a total of $229.11M.

  • Who are the investors of Aura Biosciences?

    Investors of Aura Biosciences include Ysios Capital Partners, Lundbeckfond Ventures, Chiesi Ventures, Arix Bioscience, Columbus Venture Partners and 17 more.

  • Who are Aura Biosciences's competitors?

    Competitors of Aura Biosciences include Catalent, Intercell, Glide Pharma, Pacira Biosciences, Azaya Therapeutics and 11 more.

You May Also Like

F
FORMAC Pharmaceuticals N.V.

FORMAC is a pharmaceutical R&D company engaged in drug delivery and development. The firm aims to increase pharmaceutical R&D productivity and product value by enhancing the performance of (pre)clinical drug candidates and marketed drugs.

K
Kucera Pharmaceutical Company

Kucera Pharmaceutical Company is based in Winston-Salem, NC. The company started with a drug delivery approach that combined or conjugated delivery molecules with therapeutic molecules as a platform technology, both to improve the properties of the attached therapeutic molecules (making them orally available and improving distribution) and to extend patent life.

E
Eratech srl

Eratech is a drug development company specialized in the field of inhalation drug delivery via nasal and pulmonary administration, for local and systemic therapies. Eratech offers to its clients the following selection of product development support services: Pharmacological-Toxicological, Pharmaceutical Development, Clinical Trials, Regulatory Affairs. nnn

C
Capsutech

CapsuTech is a product driven company focused on research and development of semi-natural, peptide-based, polymers for drug targeting and encapsulation of various chemical and biological entities. Such entities might be drugs, cosmetics, vitamins, food additives, proteins, virions and even cells.nVarious combinations of CapsuTech's modified amino-acid building-blocks provide high-diversity population of polymers and thus enable to formulate almost all molecules and to meet wide spectrum of needs. Such needs include targeting, site-specific release, controlled release. Other characteristics include protection from pH, enzyme proteolysis, oxidation, light and other damaging factors.

O
Optotrack

Optotrack, Inc. is a high-tech company leading in the research and development of optical, imaging, chemical, as well as biological sensors and microsystems. The company is dedicated to commercializing its intellectual properties based on microfabrication and nanotechnology to seize rapidly growing market opportunities in the industries of healthcare, communication, and homeland security. Optotrack, Inc. offers a broad range of technology and business solutions from design through production to marketing and sales. The company combine decades of industry experience and R&D expertise in thin-film science, polymer engineering, solid-state sensing, digital imaging, optoelectronics, RF circuitry, medical diagnostics, microfluidics, and drug delivery to provide enabling technologies to the company's partners, customers, and community. The firm aims to deliver products and services of exceptional quality to cast the future, to improve the life quality for everyone.

M
MedManage Systems

MedManage Systems, Inc. aims to provide drug sampling solutions. The company's OmniSampleSM Solution aims to allow pharmaceutical companies to intensify physician use of trial medications, thereby increasing product revenues.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.